AU2005279835A1 - Chemical compounds - Google Patents

Info

Publication number

AU2005279835A1

AU2005279835A1 AU2005279835A AU2005279835A AU2005279835A1 AU 2005279835 A1 AU2005279835 A1 AU 2005279835A1 AU 2005279835 A AU2005279835 A AU 2005279835A AU 2005279835 A AU2005279835 A AU 2005279835A AU 2005279835 A1 AU2005279835 A1 AU 2005279835A1

Authority

AU

Australia

Prior art keywords

methyl

alkyl

compound

tetrahydro

imidazo

Prior art date

2004-09-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 352
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 221
• 125000000217 alkyl group Chemical group 0.000 claims description 179
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 122
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 114
• -1 Ethyloxy Chemical group 0.000 claims description 78
• 125000003342 alkenyl group Chemical group 0.000 claims description 75
• 125000000304 alkynyl group Chemical group 0.000 claims description 75
• 239000007787 solid Substances 0.000 claims description 62
• 125000001188 haloalkyl group Chemical group 0.000 claims description 60
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 53
• 239000000203 mixture Substances 0.000 claims description 48
• 238000006268 reductive amination reaction Methods 0.000 claims description 47
• 238000000034 method Methods 0.000 claims description 44
• 238000011282 treatment Methods 0.000 claims description 44
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 43
• 229910052736 halogen Inorganic materials 0.000 claims description 40
• 150000002367 halogens Chemical group 0.000 claims description 40
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
• 239000003795 chemical substances by application Substances 0.000 claims description 37
• 150000003839 salts Chemical class 0.000 claims description 35
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 33
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 31
• UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims description 31
• 230000000694 effects Effects 0.000 claims description 29
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 26
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 25
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 24
• 201000010099 disease Diseases 0.000 claims description 23
• 239000008194 pharmaceutical composition Substances 0.000 claims description 23
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 21
• 238000005859 coupling reaction Methods 0.000 claims description 21
• 125000000623 heterocyclic group Chemical group 0.000 claims description 21
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
• 125000002947 alkylene group Chemical group 0.000 claims description 20
• 125000004043 oxo group Chemical group O=* 0.000 claims description 20
• 230000009467 reduction Effects 0.000 claims description 20
• 238000006722 reduction reaction Methods 0.000 claims description 20
• 208000031886 HIV Infections Diseases 0.000 claims description 19
• 208000037357 HIV infectious disease Diseases 0.000 claims description 19
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 19
• 229910052739 hydrogen Inorganic materials 0.000 claims description 19
• 230000008878 coupling Effects 0.000 claims description 17
• 238000010168 coupling process Methods 0.000 claims description 17
• 238000011321 prophylaxis Methods 0.000 claims description 17
• 102000009410 Chemokine receptor Human genes 0.000 claims description 16
• 108050000299 Chemokine receptor Proteins 0.000 claims description 16
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 15
• 125000001072 heteroaryl group Chemical group 0.000 claims description 15
• 230000002757 inflammatory effect Effects 0.000 claims description 15
• 230000008569 process Effects 0.000 claims description 15
• 201000004624 Dermatitis Diseases 0.000 claims description 14
• 201000004681 Psoriasis Diseases 0.000 claims description 14
• 208000026935 allergic disease Diseases 0.000 claims description 14
• 230000002708 enhancing effect Effects 0.000 claims description 14
• 230000009610 hypersensitivity Effects 0.000 claims description 14
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 13
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 13
• 206010061218 Inflammation Diseases 0.000 claims description 13
• 206010028980 Neoplasm Diseases 0.000 claims description 13
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 13
• 230000004054 inflammatory process Effects 0.000 claims description 13
• 125000001424 substituent group Chemical group 0.000 claims description 13
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 13
• 210000001519 tissue Anatomy 0.000 claims description 13
• 125000005724 cycloalkenylene group Chemical group 0.000 claims description 12
• 125000002993 cycloalkylene group Chemical group 0.000 claims description 12
• 150000002148 esters Chemical class 0.000 claims description 12
• 125000004450 alkenylene group Chemical group 0.000 claims description 11
• 125000003282 alkyl amino group Chemical group 0.000 claims description 11
• 125000004419 alkynylene group Chemical group 0.000 claims description 11
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
• 125000003545 alkoxy group Chemical group 0.000 claims description 10
• 125000000000 cycloalkoxy group Chemical group 0.000 claims description 10
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 10
• 239000003112 inhibitor Substances 0.000 claims description 10
• 125000003107 substituted aryl group Chemical group 0.000 claims description 10
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
• 208000035475 disorder Diseases 0.000 claims description 9
• 208000006673 asthma Diseases 0.000 claims description 8
• 208000032839 leukemia Diseases 0.000 claims description 8
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 8
• 239000002773 nucleotide Substances 0.000 claims description 8
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
• 206010058284 Allergy to arthropod sting Diseases 0.000 claims description 7
• 206010002198 Anaphylactic reaction Diseases 0.000 claims description 7
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 7
• 208000023275 Autoimmune disease Diseases 0.000 claims description 7
• 208000035143 Bacterial infection Diseases 0.000 claims description 7
• 208000011231 Crohn disease Diseases 0.000 claims description 7
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
• 206010012442 Dermatitis contact Diseases 0.000 claims description 7
• 206010013700 Drug hypersensitivity Diseases 0.000 claims description 7
• 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 7
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 7
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 7
• 206010020751 Hypersensitivity Diseases 0.000 claims description 7
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims description 7
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 7
• 208000019693 Lung disease Diseases 0.000 claims description 7
• 241000288894 Myotis Species 0.000 claims description 7
• 206010035664 Pneumonia Diseases 0.000 claims description 7
• 206010035742 Pneumonitis Diseases 0.000 claims description 7
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 7
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 7
• 206010039085 Rhinitis allergic Diseases 0.000 claims description 7
• 206010039710 Scleroderma Diseases 0.000 claims description 7
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
• 208000006045 Spondylarthropathies Diseases 0.000 claims description 7
• 201000009594 Systemic Scleroderma Diseases 0.000 claims description 7
• 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
• 206010052779 Transplant rejections Diseases 0.000 claims description 7
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 7
• 208000025865 Ulcer Diseases 0.000 claims description 7
• 208000024780 Urticaria Diseases 0.000 claims description 7
• 206010047115 Vasculitis Diseases 0.000 claims description 7
• 208000002029 allergic contact dermatitis Diseases 0.000 claims description 7
• 201000010105 allergic rhinitis Diseases 0.000 claims description 7
• 208000003455 anaphylaxis Diseases 0.000 claims description 7
• 201000008937 atopic dermatitis Diseases 0.000 claims description 7
• 208000010668 atopic eczema Diseases 0.000 claims description 7
• 230000001363 autoimmune Effects 0.000 claims description 7
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
• 238000010322 bone marrow transplantation Methods 0.000 claims description 7
• 238000002512 chemotherapy Methods 0.000 claims description 7
• 201000001981 dermatomyositis Diseases 0.000 claims description 7
• 230000002327 eosinophilic effect Effects 0.000 claims description 7
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 7
• 208000024908 graft versus host disease Diseases 0.000 claims description 7
• 230000011132 hemopoiesis Effects 0.000 claims description 7
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 7
• 201000006362 hypersensitivity vasculitis Diseases 0.000 claims description 7
• 208000027866 inflammatory disease Diseases 0.000 claims description 7
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• 230000002956 necrotizing effect Effects 0.000 claims description 7
• 125000003729 nucleotide group Chemical group 0.000 claims description 7
• 208000005987 polymyositis Diseases 0.000 claims description 7
• 208000017520 skin disease Diseases 0.000 claims description 7
• 201000005671 spondyloarthropathy Diseases 0.000 claims description 7
• 230000005951 type IV hypersensitivity Effects 0.000 claims description 7
• 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 7
• 230000029663 wound healing Effects 0.000 claims description 7
• QUDMHFVRKBVGBY-FQEVSTJZSA-N [5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 QUDMHFVRKBVGBY-FQEVSTJZSA-N 0.000 claims description 6
• NJBRZHKNUUOYBN-QFIPXVFZSA-N [5-(4-methylpiperazin-1-yl)-2-[[propan-2-yl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CC(C)N([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 NJBRZHKNUUOYBN-QFIPXVFZSA-N 0.000 claims description 6
• WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 6
• 210000004556 brain Anatomy 0.000 claims description 6
• 210000000481 breast Anatomy 0.000 claims description 6
• 201000011510 cancer Diseases 0.000 claims description 6
• WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 210000004072 lung Anatomy 0.000 claims description 6
• NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 6
• CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 claims description 6
• 229950008687 oltipraz Drugs 0.000 claims description 6
• 210000002307 prostate Anatomy 0.000 claims description 6
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 6
• 230000001225 therapeutic effect Effects 0.000 claims description 6
• OMQGJJGRSZIQQJ-QHCPKHFHSA-N [2-[[cyclopropylmethyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CN(CC3CC3)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 OMQGJJGRSZIQQJ-QHCPKHFHSA-N 0.000 claims description 5
• VCFMOLJXJJHRDI-NRFANRHFSA-N [2-[[ethyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 VCFMOLJXJJHRDI-NRFANRHFSA-N 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 239000000126 substance Substances 0.000 claims description 5
• 229940124597 therapeutic agent Drugs 0.000 claims description 5
• BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
• 229940044613 1-propanol Drugs 0.000 claims description 4
• MZRHSBOFBICIAU-FIPFOOKPSA-N [2-[[[(1s)-1-(4-methoxyphenyl)ethyl]-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1=CC(OC)=CC=C1[C@H](C)N([C@@H]1C2=NC=CC=C2CCC1)CC1=C(CO)N2C(N3CCN(C)CC3)=CC=CC2=N1 MZRHSBOFBICIAU-FIPFOOKPSA-N 0.000 claims description 4
• UAWUQXPDPOEYPP-VWNXMTODSA-N [2-[[cyclopropylmethyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1[C@H](N(C)C)CCN1C1=CC=CC2=NC(CN(CC3CC3)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 UAWUQXPDPOEYPP-VWNXMTODSA-N 0.000 claims description 4
• ITOXKJBXAWDJBA-NRFANRHFSA-N [5-(4-ethylpiperazin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CN(CC)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 ITOXKJBXAWDJBA-NRFANRHFSA-N 0.000 claims description 4
• HGWYUSJZJFIGOG-QFIPXVFZSA-N [5-(4-methylpiperazin-1-yl)-2-[[propyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCCN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 HGWYUSJZJFIGOG-QFIPXVFZSA-N 0.000 claims description 4
• CZWUXDXQKLXFBS-CTNGQTDRSA-N [5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1[C@H](N(C)C)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 CZWUXDXQKLXFBS-CTNGQTDRSA-N 0.000 claims description 4
• FMKQGTBQHSFAOK-GGAORHGYSA-N [5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-[[propyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCCN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CC[C@@H](N(C)C)C1 FMKQGTBQHSFAOK-GGAORHGYSA-N 0.000 claims description 4
• DBLIBYXKCXRXKI-QWAKEFERSA-N [5-[methyl-(1-methylpyrrolidin-3-yl)amino]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N(C)C1CCN(C)C1 DBLIBYXKCXRXKI-QWAKEFERSA-N 0.000 claims description 4
• 239000003054 catalyst Substances 0.000 claims description 4
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
• QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 3
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 3
• XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 3
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 3
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 3
• IBHARWXWOCPXCR-WELGVCPWSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 IBHARWXWOCPXCR-WELGVCPWSA-N 0.000 claims description 3
• QUDMHFVRKBVGBY-UHFFFAOYSA-N [5-(4-methylpiperazin-1-yl)-2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CCC2=CC=CN=C2C1N(C)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 QUDMHFVRKBVGBY-UHFFFAOYSA-N 0.000 claims description 3
• QWHDVDASMCRJJZ-UHFFFAOYSA-N [5-(4-methylpiperazin-1-yl)-2-[[methyl(6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl)amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CCCC2=CC=CN=C2C1N(C)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 QWHDVDASMCRJJZ-UHFFFAOYSA-N 0.000 claims description 3
• CYYJZCMKOQFVEU-IRLDBZIGSA-N [5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-[[ethyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CC[C@@H](N(C)C)C1 CYYJZCMKOQFVEU-IRLDBZIGSA-N 0.000 claims description 3
• LJZYHHSTUCZUCV-QUCCMNQESA-N [5-[(3r)-3-(methylamino)pyrrolidin-1-yl]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1[C@H](NC)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 LJZYHHSTUCZUCV-QUCCMNQESA-N 0.000 claims description 3
• BIABECXOMDEQRN-MJGOQNOKSA-N [5-[(3r)-3-aminopyrrolidin-1-yl]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CC[C@@H](N)C1 BIABECXOMDEQRN-MJGOQNOKSA-N 0.000 claims description 3
• TZXUJAFBNRHKQL-FQEVSTJZSA-N [5-[2-(dimethylamino)ethyl-methylamino]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=C(CO)N2C(N(C)CCN(C)C)=CC=CC2=N1 TZXUJAFBNRHKQL-FQEVSTJZSA-N 0.000 claims description 3
• 229960004748 abacavir Drugs 0.000 claims description 3
• MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 3
• 229960001997 adefovir Drugs 0.000 claims description 3
• 229960003205 adefovir dipivoxil Drugs 0.000 claims description 3
• 150000001412 amines Chemical group 0.000 claims description 3
• 230000003064 anti-oxidating effect Effects 0.000 claims description 3
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
• 230000034303 cell budding Effects 0.000 claims description 3
• 229960005319 delavirdine Drugs 0.000 claims description 3
• 229960002656 didanosine Drugs 0.000 claims description 3
• XNHZXMPLVSJQFK-UHFFFAOYSA-O dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium Chemical compound C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 XNHZXMPLVSJQFK-UHFFFAOYSA-O 0.000 claims description 3
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
• XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 3
• 229960003804 efavirenz Drugs 0.000 claims description 3
• 229950010245 ibalizumab Drugs 0.000 claims description 3
• CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
• 229960001936 indinavir Drugs 0.000 claims description 3
• 239000002850 integrase inhibitor Substances 0.000 claims description 3
• 229940124524 integrase inhibitor Drugs 0.000 claims description 3
• 229960001627 lamivudine Drugs 0.000 claims description 3
• JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
• 229950004697 lasinavir Drugs 0.000 claims description 3
• 229940121292 leronlimab Drugs 0.000 claims description 3
• CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 3
• 229950006243 loviride Drugs 0.000 claims description 3
• QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 3
• 229960000884 nelfinavir Drugs 0.000 claims description 3
• 229960000689 nevirapine Drugs 0.000 claims description 3
• RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 claims description 3
• 229950006460 palinavir Drugs 0.000 claims description 3
• 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 3
• 229960000311 ritonavir Drugs 0.000 claims description 3
• QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 3
• 229960001852 saquinavir Drugs 0.000 claims description 3
• BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 claims description 3
• 229960000523 zalcitabine Drugs 0.000 claims description 3
• 229960002555 zidovudine Drugs 0.000 claims description 3
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
• TXIOIJSYWOLKNU-FLQODOFBSA-N (1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1 Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C TXIOIJSYWOLKNU-FLQODOFBSA-N 0.000 claims description 2
• CXISALFKUJXLHF-UHFFFAOYSA-N 2,2,2-trifluoro-1-[5-(4-methylpiperazin-1-yl)-2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]imidazo[1,2-a]pyridin-3-yl]ethanol Chemical compound C1CCC2=CC=CN=C2C1N(C)CC(=C(N12)C(O)C(F)(F)F)N=C1C=CC=C2N1CCN(C)CC1 CXISALFKUJXLHF-UHFFFAOYSA-N 0.000 claims description 2
• 108010036239 CD4-IgG(2) Proteins 0.000 claims description 2
• HEFHSVQEDGDAGF-FQEVSTJZSA-N [5-(4-aminopiperidin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCC(N)CC1 HEFHSVQEDGDAGF-FQEVSTJZSA-N 0.000 claims description 2
• IUTANJSSQZHMSG-IJHRGXPZSA-N [5-(4-methylpiperazin-1-yl)-2-[1-[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]ethyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)C(C)C(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 IUTANJSSQZHMSG-IJHRGXPZSA-N 0.000 claims description 2
• XHGQCPHNQYYJRF-SANMLTNESA-N [5-(4-methylpiperazin-1-yl)-2-[[[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CN(CC=3C=CC(=CC=3)C(F)(F)F)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 XHGQCPHNQYYJRF-SANMLTNESA-N 0.000 claims description 2
• HVPCZNXEQMRZRX-GGAORHGYSA-N [5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-[[propan-2-yl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CC(C)N([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CC[C@@H](N(C)C)C1 HVPCZNXEQMRZRX-GGAORHGYSA-N 0.000 claims description 2
• CZWUXDXQKLXFBS-FPOVZHCZSA-N [5-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 CZWUXDXQKLXFBS-FPOVZHCZSA-N 0.000 claims description 2
• 150000003973 alkyl amines Chemical group 0.000 claims description 2
• 125000003386 piperidinyl group Chemical group 0.000 claims description 2
• OKGPFTLYBPQBIX-CQSZACIVSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CC=NC=2NC=C1C(=O)C(=O)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 OKGPFTLYBPQBIX-CQSZACIVSA-N 0.000 claims 2
• 230000002378 acidificating effect Effects 0.000 claims 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
• 208000036142 Viral infection Diseases 0.000 claims 1
• FWHLIPKBOBBOAB-SANMLTNESA-N [2-[[benzyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CN(CC=3C=CC=CC=3)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 FWHLIPKBOBBOAB-SANMLTNESA-N 0.000 claims 1
• OSKWWXWMHXCEBW-QFIPXVFZSA-N [2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CN(C(C)C)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=C(CO)N12 OSKWWXWMHXCEBW-QFIPXVFZSA-N 0.000 claims 1
• 230000009385 viral infection Effects 0.000 claims 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 213
• 238000005481 NMR spectroscopy Methods 0.000 description 80
• 238000006243 chemical reaction Methods 0.000 description 79
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 75
• 239000003921 oil Substances 0.000 description 65
• 235000019198 oils Nutrition 0.000 description 63
• 239000000243 solution Substances 0.000 description 61
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 53
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
• 210000004027 cell Anatomy 0.000 description 52
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 40
• 239000002904 solvent Substances 0.000 description 39
• 238000005160 1H NMR spectroscopy Methods 0.000 description 36
• 238000007031 hydroxymethylation reaction Methods 0.000 description 35
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 33
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
• 239000012044 organic layer Substances 0.000 description 31
• 235000002639 sodium chloride Nutrition 0.000 description 31
• 229920006395 saturated elastomer Polymers 0.000 description 30
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 28
• 238000010511 deprotection reaction Methods 0.000 description 27
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 27
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 25
• 239000002253 acid Substances 0.000 description 25
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
• 241000725303 Human immunodeficiency virus Species 0.000 description 20
• 229960000583 acetic acid Drugs 0.000 description 20
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 20
• 235000019341 magnesium sulphate Nutrition 0.000 description 20
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
• 235000019441 ethanol Nutrition 0.000 description 18
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
• 235000019439 ethyl acetate Nutrition 0.000 description 17
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
• 235000020127 ayran Nutrition 0.000 description 16
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 16
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• 238000003786 synthesis reaction Methods 0.000 description 15
• JFJRWADANRJCCO-HNNXBMFYSA-N (8s)-n-[(5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=CN(C(F)=CC=C2)C2=N1 JFJRWADANRJCCO-HNNXBMFYSA-N 0.000 description 14
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 14
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 14
• 239000000908 ammonium hydroxide Substances 0.000 description 14
• 239000003638 chemical reducing agent Substances 0.000 description 14
• 238000003818 flash chromatography Methods 0.000 description 14
• 238000009472 formulation Methods 0.000 description 14
• 229910000029 sodium carbonate Inorganic materials 0.000 description 14
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
• 238000007792 addition Methods 0.000 description 12
• 238000006073 displacement reaction Methods 0.000 description 12
• 239000010410 layer Substances 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 239000000843 powder Substances 0.000 description 12
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 11
• 125000003118 aryl group Chemical group 0.000 description 11
• 229910052757 nitrogen Inorganic materials 0.000 description 11
• 239000012453 solvate Substances 0.000 description 11
• JQGOUNFVDYUKMM-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CN=C2C(N)CCCC2=C1 JQGOUNFVDYUKMM-UHFFFAOYSA-N 0.000 description 10
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 10
• 150000001299 aldehydes Chemical class 0.000 description 10
• 239000000460 chlorine Substances 0.000 description 10
• 239000011541 reaction mixture Substances 0.000 description 10
• 239000011734 sodium Substances 0.000 description 10
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 239000000377 silicon dioxide Substances 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• LILSBXJJIIFDGR-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-8-amine Chemical compound C1CCNC2=C1C=CC=C2N LILSBXJJIIFDGR-UHFFFAOYSA-N 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 8
• 239000005089 Luciferase Substances 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• 235000017557 sodium bicarbonate Nutrition 0.000 description 8
• 239000012279 sodium borohydride Substances 0.000 description 8
• 229910000033 sodium borohydride Inorganic materials 0.000 description 8
• 239000003826 tablet Substances 0.000 description 8
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
• 235000019502 Orange oil Nutrition 0.000 description 7
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 239000012894 fetal calf serum Substances 0.000 description 7
• 239000012362 glacial acetic acid Substances 0.000 description 7
• 239000012442 inert solvent Substances 0.000 description 7
• 239000010502 orange oil Substances 0.000 description 7
• 230000003647 oxidation Effects 0.000 description 7
• 238000007254 oxidation reaction Methods 0.000 description 7
• 238000004237 preparative chromatography Methods 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
• YFMYMVJGOKBODC-FIPFOOKPSA-N (8s)-n-[(1s)-1-(4-methoxyphenyl)ethyl]-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(OC)=CC=C1[C@H](C)N([C@@H]1C2=NC=CC=C2CCC1)CC1=CN(C(=CC=C2)N3CCN(C)CC3)C2=N1 YFMYMVJGOKBODC-FIPFOOKPSA-N 0.000 description 6
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 6
• ICFHDYFCVQPVHM-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridine-2-carbaldehyde Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(C=O)=CN12 ICFHDYFCVQPVHM-UHFFFAOYSA-N 0.000 description 6
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 6
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 6
• 229910021529 ammonia Inorganic materials 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 125000004432 carbon atom Chemical group C* 0.000 description 6
• 229930195733 hydrocarbon Natural products 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
• 239000012038 nucleophile Substances 0.000 description 6
• 125000004193 piperazinyl group Chemical group 0.000 description 6
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 239000002002 slurry Substances 0.000 description 6
• 229910052708 sodium Inorganic materials 0.000 description 6
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
• ANTIOTRWBFOORM-UHFFFAOYSA-N 5-fluoroimidazo[1,2-a]pyridine-2-carbaldehyde Chemical compound FC1=CC=CC2=NC(C=O)=CN12 ANTIOTRWBFOORM-UHFFFAOYSA-N 0.000 description 5
• JIAKIQWNYAZUJD-UHFFFAOYSA-N 6,7-dihydro-5h-quinolin-8-one Chemical compound C1=CN=C2C(=O)CCCC2=C1 JIAKIQWNYAZUJD-UHFFFAOYSA-N 0.000 description 5
• UZALKVXCOUSWSL-UHFFFAOYSA-N 6-fluoropyridin-2-amine Chemical compound NC1=CC=CC(F)=N1 UZALKVXCOUSWSL-UHFFFAOYSA-N 0.000 description 5
• 101150041968 CDC13 gene Proteins 0.000 description 5
• 239000004215 Carbon black (E152) Substances 0.000 description 5
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 5
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 5
• 101710090322 Truncated surface protein Proteins 0.000 description 5
• 230000036436 anti-hiv Effects 0.000 description 5
• JXLPJCAIPGVFAA-UHFFFAOYSA-N azanium;acetonitrile;hydroxide Chemical compound [NH4+].[OH-].CC#N JXLPJCAIPGVFAA-UHFFFAOYSA-N 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 238000010438 heat treatment Methods 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 238000004809 thin layer chromatography Methods 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• 238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 5
• ZWILTCXCTVMANU-UHFFFAOYSA-N 1,1,3-trichloropropan-2-one Chemical compound ClCC(=O)C(Cl)Cl ZWILTCXCTVMANU-UHFFFAOYSA-N 0.000 description 4
• MKPYXJBRSQWUJN-UHFFFAOYSA-N 5-bromoimidazo[1,2-a]pyridine-2-carbaldehyde Chemical compound BrC1=CC=CC2=NC(C=O)=CN12 MKPYXJBRSQWUJN-UHFFFAOYSA-N 0.000 description 4
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 4
• 241001328813 Methles Species 0.000 description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• JFJRWADANRJCCO-UHFFFAOYSA-N n-[(5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=CN(C(F)=CC=C2)C2=N1 JFJRWADANRJCCO-UHFFFAOYSA-N 0.000 description 4
• ZXTRMHOUGKPHHM-UHFFFAOYSA-N n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CN=C2C(NC)CCCC2=C1 ZXTRMHOUGKPHHM-UHFFFAOYSA-N 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 150000004885 piperazines Chemical class 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
• 239000012312 sodium hydride Substances 0.000 description 4
• 229910000104 sodium hydride Inorganic materials 0.000 description 4
• 229910052938 sodium sulfate Inorganic materials 0.000 description 4
• 235000011152 sodium sulphate Nutrition 0.000 description 4
• 238000001228 spectrum Methods 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• JTDGKQNNPKXKII-ZETCQYMHSA-N (1s)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@H](C)N)C=C1 JTDGKQNNPKXKII-ZETCQYMHSA-N 0.000 description 3
• HWIWZEQASCSYJM-CXAGYDPISA-N (8r)-n-[(1r)-1-(4-methoxyphenyl)ethyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(OC)=CC=C1[C@@H](C)N[C@H]1C2=NC=CC=C2CCC1 HWIWZEQASCSYJM-CXAGYDPISA-N 0.000 description 3
• HWIWZEQASCSYJM-GUYCJALGSA-N (8s)-n-[(1s)-1-(4-methoxyphenyl)ethyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(OC)=CC=C1[C@H](C)N[C@@H]1C2=NC=CC=C2CCC1 HWIWZEQASCSYJM-GUYCJALGSA-N 0.000 description 3
• ZXTRMHOUGKPHHM-VIFPVBQESA-N (8s)-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CN=C2[C@@H](NC)CCCC2=C1 ZXTRMHOUGKPHHM-VIFPVBQESA-N 0.000 description 3
• FRHRAPSVOIMXJY-FQEVSTJZSA-N (8s)-n-methyl-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 FRHRAPSVOIMXJY-FQEVSTJZSA-N 0.000 description 3
• XZLMELLMHWWEMK-ZYZRXSCRSA-N 1-[5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]ethanol Chemical compound N12C(C(O)C)=C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)N=C2C=CC=C1N1CCN(C)CC1 XZLMELLMHWWEMK-ZYZRXSCRSA-N 0.000 description 3
• WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 3
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
• IXOVJHWQNJYEPQ-UHFFFAOYSA-N 2-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC(N)C2=NC(C)=CC=C21 IXOVJHWQNJYEPQ-UHFFFAOYSA-N 0.000 description 3
• DCPKEQUJEBWILH-FQEVSTJZSA-N 5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridine-3-carbaldehyde Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)C=O)N=C1C=CC=C2N1CCN(C)CC1 DCPKEQUJEBWILH-FQEVSTJZSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 238000005576 amination reaction Methods 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 230000007910 cell fusion Effects 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 3
• SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000006260 foam Substances 0.000 description 3
• 239000008098 formaldehyde solution Substances 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
• RTYCIUZFGNBFDO-UHFFFAOYSA-N n-[[5-(4-ethylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(CC)CCN1C1=CC=CC2=NC(CN(C)C3C4=NC=CC=C4CCC3)=CN12 RTYCIUZFGNBFDO-UHFFFAOYSA-N 0.000 description 3
• FRHRAPSVOIMXJY-UHFFFAOYSA-N n-methyl-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 FRHRAPSVOIMXJY-UHFFFAOYSA-N 0.000 description 3
• MFPNAWHIPSNSRA-UHFFFAOYSA-N n-methyl-n-[[5-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(C(C)C)CCN1C1=CC=CC2=NC(CN(C)C3C4=NC=CC=C4CCC3)=CN12 MFPNAWHIPSNSRA-UHFFFAOYSA-N 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 229910000027 potassium carbonate Inorganic materials 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• NRQKORLEIODHSQ-UHFFFAOYSA-N tert-butyl 4-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]imidazo[1,2-a]pyridin-5-yl]piperazine-1-carboxylate Chemical compound C1CCC2=CC=CN=C2C1N(C)CC(N=C1C=CC=2)=CN1C=2N1CCN(C(=O)OC(C)(C)C)CC1 NRQKORLEIODHSQ-UHFFFAOYSA-N 0.000 description 3
• 238000011200 topical administration Methods 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• AVAWMINJNRAQFS-ZCFIWIBFSA-N (3r)-n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)[C@@H]1CCNC1 AVAWMINJNRAQFS-ZCFIWIBFSA-N 0.000 description 2
• JKFPKLUYRZNUGK-UHFFFAOYSA-N (5-fluoroimidazo[1,2-a]pyridin-2-yl)methanol Chemical compound FC1=CC=CC2=NC(CO)=CN21 JKFPKLUYRZNUGK-UHFFFAOYSA-N 0.000 description 2
• RVWPTIDXLRPTRW-WZONZLPQSA-N (8r)-n-[(5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl]-n-[(1r)-1-(4-methoxyphenyl)ethyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(OC)=CC=C1[C@@H](C)N([C@H]1C2=NC=CC=C2CCC1)CC1=CN(C(F)=CC=C2)C2=N1 RVWPTIDXLRPTRW-WZONZLPQSA-N 0.000 description 2
• RCYCSJCAJKWPGT-QFIPXVFZSA-N (8s)-n-[[3-(ethoxymethyl)-5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N12C(COCC)=C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)N=C2C=CC=C1N1CCN(C)CC1 RCYCSJCAJKWPGT-QFIPXVFZSA-N 0.000 description 2
• UNJUOXFDBJBZSL-FQEVSTJZSA-N (8s)-n-[[5-(1,4-diazepan-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCCNCC1 UNJUOXFDBJBZSL-FQEVSTJZSA-N 0.000 description 2
• MJKGXNDWAPDFFX-SANMLTNESA-N (8s)-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-[[4-(trifluoromethyl)phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CN(CC=3C=CC(=CC=3)C(F)(F)F)[C@@H]3C4=NC=CC=C4CCC3)=CN12 MJKGXNDWAPDFFX-SANMLTNESA-N 0.000 description 2
• QJSUPMMHOXHUJT-QFIPXVFZSA-N (8s)-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-propan-2-yl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)N([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 QJSUPMMHOXHUJT-QFIPXVFZSA-N 0.000 description 2
• VLKZZNVOWQCIBI-QFIPXVFZSA-N (8s)-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-propyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCCN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 VLKZZNVOWQCIBI-QFIPXVFZSA-N 0.000 description 2
• DUXQJVSQUNTORQ-PKTZIBPZSA-N (8s)-n-[[5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-propan-2-yl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)N([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CC[C@@H](N(C)C)C1 DUXQJVSQUNTORQ-PKTZIBPZSA-N 0.000 description 2
• VAZJISFHBCFPSG-FVGYRXGTSA-N (8s)-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CN=C2[C@@H](NC)CCCC2=C1 VAZJISFHBCFPSG-FVGYRXGTSA-N 0.000 description 2
• MFPNAWHIPSNSRA-QFIPXVFZSA-N (8s)-n-methyl-n-[[5-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(C(C)C)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=CN12 MFPNAWHIPSNSRA-QFIPXVFZSA-N 0.000 description 2
• KGGOEFQJWNRJEG-LBAQZLPGSA-N (8s)-n-methyl-n-[[5-[methyl-(1-methylpyrrolidin-3-yl)amino]imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N(C)C1CCN(C)C1 KGGOEFQJWNRJEG-LBAQZLPGSA-N 0.000 description 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
• IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 2
• SMZHKGXSEAGRTI-UHFFFAOYSA-N 1,1,1-trichloropropan-2-one Chemical compound CC(=O)C(Cl)(Cl)Cl SMZHKGXSEAGRTI-UHFFFAOYSA-N 0.000 description 2
• SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• DTCWSXDBKSRIKY-UHFFFAOYSA-N 1-[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]ethanone Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(C(C)=O)=CN12 DTCWSXDBKSRIKY-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
• JFIIICGKUFLQNF-UHFFFAOYSA-N 2-(chloromethyl)-5-fluoroimidazo[1,2-a]pyridine Chemical compound FC1=CC=CC2=NC(CCl)=CN12 JFIIICGKUFLQNF-UHFFFAOYSA-N 0.000 description 2
• YCOFITAQIPULIF-UHFFFAOYSA-N 2-(dichloromethyl)-5-fluoroimidazo[1,2-a]pyridine Chemical compound FC1=CC=CC2=NC(C(Cl)Cl)=CN12 YCOFITAQIPULIF-UHFFFAOYSA-N 0.000 description 2
• YCYJZUODTCSPPB-UHFFFAOYSA-N 5,6,7,8-tetrahydrocyclohepta[b]pyridin-9-one Chemical compound O=C1CCCCC2=CC=CN=C12 YCYJZUODTCSPPB-UHFFFAOYSA-N 0.000 description 2
• CVNHXFZQLVNFRS-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-ol Chemical compound OC1CCCCC2=CC=CN=C12 CVNHXFZQLVNFRS-UHFFFAOYSA-N 0.000 description 2
• BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 239000012448 Lithium borohydride Substances 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
• NDLWKLMYOAVWPJ-UHFFFAOYSA-N [5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methanol Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CO)=CN12 NDLWKLMYOAVWPJ-UHFFFAOYSA-N 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 238000002820 assay format Methods 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 229910000085 borane Inorganic materials 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 230000022244 formylation Effects 0.000 description 2
• 238000006170 formylation reaction Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 102000053523 human CXCR4 Human genes 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 2
• GAADRYBSBDOGTN-UHFFFAOYSA-N n-[(5-bromoimidazo[1,2-a]pyridin-2-yl)methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=CN(C(Br)=CC=C2)C2=N1 GAADRYBSBDOGTN-UHFFFAOYSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• GFUWGFQAWNECAP-UHFFFAOYSA-N n-methyl-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-amine Chemical compound CNC1CCCCC2=CC=CN=C12 GFUWGFQAWNECAP-UHFFFAOYSA-N 0.000 description 2
• JPTZJWVMCKRUDC-UHFFFAOYSA-N n-propan-2-yl-n-[[5-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C(C)C)CC(N=C1C=CC=2)=CN1C=2N1CCN(C(C)C)CC1 JPTZJWVMCKRUDC-UHFFFAOYSA-N 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 235000006408 oxalic acid Nutrition 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• 229950010131 puromycin Drugs 0.000 description 2
• XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000009491 slugging Methods 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 238000004611 spectroscopical analysis Methods 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 2
• 229910052815 sulfur oxide Inorganic materials 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• JTDGKQNNPKXKII-SSDOTTSWSA-N (1r)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@@H](C)N)C=C1 JTDGKQNNPKXKII-SSDOTTSWSA-N 0.000 description 1
• RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
• AVAWMINJNRAQFS-LURJTMIESA-N (3s)-n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)[C@H]1CCNC1 AVAWMINJNRAQFS-LURJTMIESA-N 0.000 description 1
• FRHRAPSVOIMXJY-HXUWFJFHSA-N (8r)-n-methyl-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 FRHRAPSVOIMXJY-HXUWFJFHSA-N 0.000 description 1
• RVWPTIDXLRPTRW-MBSDFSHPSA-N (8s)-n-[(5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl]-n-[(1s)-1-(4-methoxyphenyl)ethyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(OC)=CC=C1[C@H](C)N([C@@H]1C2=NC=CC=C2CCC1)CC1=CN(C(F)=CC=C2)C2=N1 RVWPTIDXLRPTRW-MBSDFSHPSA-N 0.000 description 1
• KWHGCXWUXUIDTC-NRFANRHFSA-N (8s)-n-[[3-(methoxymethyl)-5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N12C(COC)=C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)N=C2C=CC=C1N1CCN(C)CC1 KWHGCXWUXUIDTC-NRFANRHFSA-N 0.000 description 1
• RTYCIUZFGNBFDO-NRFANRHFSA-N (8s)-n-[[5-(4-ethylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(CC)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=CN12 RTYCIUZFGNBFDO-NRFANRHFSA-N 0.000 description 1
• BSRSSMPEWJMVCH-LCRMXPIESA-N (8s)-n-[[5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-[(1s)-1-(4-methoxyphenyl)ethyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(OC)=CC=C1[C@H](C)N([C@@H]1C2=NC=CC=C2CCC1)CC1=CN(C(=CC=C2)N3C[C@@H](CC3)N(C)C)C2=N1 BSRSSMPEWJMVCH-LCRMXPIESA-N 0.000 description 1
• GBXJUSLOSBALMG-YADHBBJMSA-N (8s)-n-[[5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-ethyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CC[C@@H](N(C)C)C1 GBXJUSLOSBALMG-YADHBBJMSA-N 0.000 description 1
• KCYJZDNOWILGPM-RTWAWAEBSA-N (8s)-n-[[5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1[C@H](N(C)C)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=CN12 KCYJZDNOWILGPM-RTWAWAEBSA-N 0.000 description 1
• UOFZOCCQDPJRLD-PKTZIBPZSA-N (8s)-n-[[5-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-propyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCCN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CC[C@@H](N(C)C)C1 UOFZOCCQDPJRLD-PKTZIBPZSA-N 0.000 description 1
• LLTLSDYWBUFMNN-MJGOQNOKSA-N (8s)-n-[[5-[(3r)-3-aminopyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CC[C@@H](N)C1 LLTLSDYWBUFMNN-MJGOQNOKSA-N 0.000 description 1
• KCYJZDNOWILGPM-SFTDATJTSA-N (8s)-n-[[5-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=CC2=NC(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=CN12 KCYJZDNOWILGPM-SFTDATJTSA-N 0.000 description 1
• QGTROIYUDZXOLO-IBGZPJMESA-N (8s)-n-[[5-[2-(dimethylamino)ethoxy]imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=CN2C(OCCN(C)C)=CC=CC2=N1 QGTROIYUDZXOLO-IBGZPJMESA-N 0.000 description 1
• BNOPLAIRDVCQBH-SANMLTNESA-N (8s)-n-benzyl-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CN(CC=3C=CC=CC=3)[C@@H]3C4=NC=CC=C4CCC3)=CN12 BNOPLAIRDVCQBH-SANMLTNESA-N 0.000 description 1
• QDYGAGPVZXUDBW-NRFANRHFSA-N (8s)-n-ethyl-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 QDYGAGPVZXUDBW-NRFANRHFSA-N 0.000 description 1
• VMDADMFTSYKUBK-NRFANRHFSA-N (8s)-n-methyl-n-[[5-(4-methyl-1,4-diazepan-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CCCN(C)CC1 VMDADMFTSYKUBK-NRFANRHFSA-N 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
• VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
• FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
• VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
• ARAOGFXYEZOODJ-HMTLIYDFSA-N 1-[5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]propan-1-ol Chemical compound N12C(C(O)CC)=C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)N=C2C=CC=C1N1CCN(C)CC1 ARAOGFXYEZOODJ-HMTLIYDFSA-N 0.000 description 1
• XNGCUBPOCIXWRJ-UHFFFAOYSA-N 1-[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]ethanol Chemical compound C=1C=CC2=NC(C(O)C)=CN2C=1N1CCN(C)CC1 XNGCUBPOCIXWRJ-UHFFFAOYSA-N 0.000 description 1
• FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• URTNWOHJPCWREM-UHFFFAOYSA-N 1h-cyclohepta[b]pyridin-9-amine Chemical compound C1=CC=CC(N)=C2NC=CC=C21 URTNWOHJPCWREM-UHFFFAOYSA-N 0.000 description 1
• MBTGBRYMJKYYOE-UHFFFAOYSA-N 2,6-difluoropyridine Chemical compound FC1=CC=CC(F)=N1 MBTGBRYMJKYYOE-UHFFFAOYSA-N 0.000 description 1
• IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 description 1
• KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
• ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 1
• OMQVWMJYEXTBGK-UHFFFAOYSA-N 2-ethyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC(N)C2=NC(CC)=CC=C21 OMQVWMJYEXTBGK-UHFFFAOYSA-N 0.000 description 1
• CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
• LVOMFTPJQWMQSD-UHFFFAOYSA-N 2-methyl-N-[[5-(2-pyrrolidin-1-ylethoxy)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC1=NC=2C(CCCC2C=C1)NCC=1N=C2N(C(=CC=C2)OCCN2CCCC2)C1 LVOMFTPJQWMQSD-UHFFFAOYSA-N 0.000 description 1
• YTGDWFSLPXLNLZ-UHFFFAOYSA-N 2-methyl-n-[1-[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]ethyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=C(C)N=C2C1NC(C)C(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 YTGDWFSLPXLNLZ-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• BABCAQJKUZUYFP-UHFFFAOYSA-N 2-propyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC(N)C2=NC(CCC)=CC=C21 BABCAQJKUZUYFP-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• CULUYAUTCSKQNM-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridine Chemical compound C1CCCCC2=CC=CN=C21 CULUYAUTCSKQNM-UHFFFAOYSA-N 0.000 description 1
• LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
• 206010065040 AIDS dementia complex Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
• 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
• 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
• 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
• 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
• 108700011778 CCR5 Proteins 0.000 description 1
• 108010041397 CD4 Antigens Proteins 0.000 description 1
• 108010061299 CXCR4 Receptors Proteins 0.000 description 1
• 102000012000 CXCR4 Receptors Human genes 0.000 description 1
• 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• YWHLKYXPLRWGSE-UHFFFAOYSA-N Dimethyl trisulfide Chemical compound CSSSC YWHLKYXPLRWGSE-UHFFFAOYSA-N 0.000 description 1
• 101100022323 Drosophila melanogaster Marf gene Proteins 0.000 description 1
• 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 208000036119 Frailty Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000237858 Gastropoda Species 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 238000003747 Grignard reaction Methods 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
• 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
• 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
• 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000796022 Homo sapiens Thioredoxin-interacting protein Proteins 0.000 description 1
• 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 241001077660 Molo Species 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229910052777 Praseodymium Inorganic materials 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 238000003120 Steady-Glo Luciferase Assay System Methods 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 230000033540 T cell apoptotic process Effects 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 102100031344 Thioredoxin-interacting protein Human genes 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010047124 Vasculitis necrotising Diseases 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• OJERPJRKPFSYOK-IAXKEJLGSA-N [5-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=C(CO)N2C(N3CC4CCCN4CC3)=CC=CC2=N1 OJERPJRKPFSYOK-IAXKEJLGSA-N 0.000 description 1
• CYISDEQXPXFRCV-NRFANRHFSA-N [5-(4-methyl-1,4-diazepan-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCCN(C)CC1 CYISDEQXPXFRCV-NRFANRHFSA-N 0.000 description 1
• QUDMHFVRKBVGBY-HXUWFJFHSA-N [5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8r)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 QUDMHFVRKBVGBY-HXUWFJFHSA-N 0.000 description 1
• WJFYCSPYGPYSFP-IBGZPJMESA-N [5-[2-(dimethylamino)ethoxy]-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=C(CO)N2C(OCCN(C)C)=CC=CC2=N1 WJFYCSPYGPYSFP-IBGZPJMESA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
• 208000037884 allergic airway inflammation Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 239000008122 artificial sweetener Substances 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 150000001555 benzenes Chemical group 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 229940090805 clavulanate Drugs 0.000 description 1
• HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004976 cyclobutylene group Chemical group 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004977 cycloheptylene group Chemical group 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000005725 cyclohexenylene group Chemical group 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004956 cyclohexylene group Chemical group 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000004979 cyclopentylene group Chemical group 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004980 cyclopropylene group Chemical group 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229950005627 embonate Drugs 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000026502 entry into host cell Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
• UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000008570 general process Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 150000002391 heterocyclic compounds Chemical class 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 102000048160 human CCR5 Human genes 0.000 description 1
• 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• QKKKBOZQZHBENG-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CN21 QKKKBOZQZHBENG-UHFFFAOYSA-N 0.000 description 1
• KIMZVDLDHKECSU-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carbaldehyde Chemical compound C1=CC=CN2C(C=O)=CN=C21 KIMZVDLDHKECSU-UHFFFAOYSA-N 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000012194 insect media Substances 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229940125425 inverse agonist Drugs 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• CZGIEJXGCLWRPY-UHFFFAOYSA-N n,1-dimethylpyrrolidin-3-amine Chemical compound CNC1CCN(C)C1 CZGIEJXGCLWRPY-UHFFFAOYSA-N 0.000 description 1
• JPVKWRVSRZEMDF-UHFFFAOYSA-N n,n,n'-trimethyl-n'-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]imidazo[1,2-a]pyridin-5-yl]ethane-1,2-diamine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=CN2C(N(C)CCN(C)C)=CC=CC2=N1 JPVKWRVSRZEMDF-UHFFFAOYSA-N 0.000 description 1
• JPVKWRVSRZEMDF-FQEVSTJZSA-N n,n,n'-trimethyl-n'-[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-5-yl]ethane-1,2-diamine Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=CN2C(N(C)CCN(C)C)=CC=CC2=N1 JPVKWRVSRZEMDF-FQEVSTJZSA-N 0.000 description 1
• SATLWVSJANHADH-UHFFFAOYSA-N n,n-dimethyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanamine Chemical compound C1=CC(CN(C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 SATLWVSJANHADH-UHFFFAOYSA-N 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• RGWHMXOWYFTILB-UHFFFAOYSA-N n-[(5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl]-n-propan-2-yl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C(C)C)CC1=CN(C(F)=CC=C2)C2=N1 RGWHMXOWYFTILB-UHFFFAOYSA-N 0.000 description 1
• GMZLORPERFPBOQ-UHFFFAOYSA-N n-[[5-(3,5-dimethylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1C(C)NC(C)CN1C1=CC=CC2=NC(CN(C)C3C4=NC=CC=C4CCC3)=CN12 GMZLORPERFPBOQ-UHFFFAOYSA-N 0.000 description 1
• YFHHDEUDFFNCEW-UHFFFAOYSA-N n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(C)CCN1C1=CC=CC2=NC(CN(CC(F)(F)F)C3C4=NC=CC=C4CCC3)=CN12 YFHHDEUDFFNCEW-UHFFFAOYSA-N 0.000 description 1
• QJSUPMMHOXHUJT-UHFFFAOYSA-N n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-propan-2-yl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C(C)C)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 QJSUPMMHOXHUJT-UHFFFAOYSA-N 0.000 description 1
• LZOHDEWKKCWXMM-UHFFFAOYSA-N n-[[5-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-n-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CN(C(C)C)CCN1C1=CC=CC2=NC(CN(CC(F)(F)F)C3C4=NC=CC=C4CCC3)=CN12 LZOHDEWKKCWXMM-UHFFFAOYSA-N 0.000 description 1
• BABAEMPTYIHDCU-UHFFFAOYSA-N n-[[5-[4-[(dimethylamino)methyl]phenyl]imidazo[1,2-a]pyridin-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(CN(C)C)=CC=C1C1=CC=CC2=NC(CN(C)C3C4=NC=CC=C4CCC3)=CN12 BABAEMPTYIHDCU-UHFFFAOYSA-N 0.000 description 1
• AQOBWZRQYWFSAW-UHFFFAOYSA-N n-methyl-n-[(5-piperazin-1-ylimidazo[1,2-a]pyridin-2-yl)methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC(N=C1C=CC=2)=CN1C=2N1CCNCC1 AQOBWZRQYWFSAW-UHFFFAOYSA-N 0.000 description 1
• IXNIIYLSQFRXKT-UHFFFAOYSA-N n-methyl-n-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-amine Chemical compound C1CCCC2=CC=CN=C2C1N(C)CC(N=C1C=CC=2)=CN1C=2N1CCN(C)CC1 IXNIIYLSQFRXKT-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 230000019581 neuron apoptotic process Effects 0.000 description 1
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000011236 particulate material Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 235000019477 peppermint oil Nutrition 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 238000013492 plasmid preparation Methods 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
• 229960002169 plerixafor Drugs 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920002721 polycyanoacrylate Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 229920005990 polystyrene resin Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• QPMDWIOUHQWKHV-ODZAUARKSA-M potassium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound [K+].OC(=O)\C=C/C([O-])=O QPMDWIOUHQWKHV-ODZAUARKSA-M 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
• 239000011253 protective coating Substances 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 230000006884 regulation of angiogenesis Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 230000002000 scavenging effect Effects 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000011257 shell material Substances 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229950002757 teoclate Drugs 0.000 description 1
• DHHKPEUQJIEKOA-UHFFFAOYSA-N tert-butyl 2-[6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetate Chemical compound C1C=CC2C(CC(=O)OC(C)(C)C)(C[N+]([O-])=O)CC21 DHHKPEUQJIEKOA-UHFFFAOYSA-N 0.000 description 1
• RYBIHKCYFOSGJS-OFNKIYASSA-N tert-butyl N-[[(3R)-1-[3-(hydroxymethyl)-2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-5-yl]pyrrolidin-3-yl]methyl]carbamate Chemical compound OCC1=C(N=C2N1C(=CC=C2)N1C[C@H](CC1)CNC(OC(C)(C)C)=O)CN([C@H]1CCCC=2C=CC=NC1=2)C RYBIHKCYFOSGJS-OFNKIYASSA-N 0.000 description 1
• DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 1
• IABAWEOTUJTREN-PKTZIBPZSA-N tert-butyl n-methyl-n-[(3r)-1-[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-5-yl]pyrrolidin-3-yl]carbamate Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(N=C1C=CC=2)=CN1C=2N1CC[C@@H](N(C)C(=O)OC(C)(C)C)C1 IABAWEOTUJTREN-PKTZIBPZSA-N 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• NLJDBTZLVTWXRG-UHFFFAOYSA-N tert-butylazanium;iodide Chemical compound [I-].CC(C)(C)[NH3+] NLJDBTZLVTWXRG-UHFFFAOYSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 229940100611 topical cream Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940100615 topical ointment Drugs 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• 229930195724 β-lactose Natural products 0.000 description 1